Home
About Us
Overview
Management
Board of Directors
Scientific Advisory Board
Technology
Overview
Production Process
Products
Overview
Collage™
Wound Management
Vergenix
WD
Wound Dressing Matrix
Vergenix
FG
Flowable Wound Gel
Orthopaedics
Vergenix
BVF
Bone Void Filler
Vergenix
TRA
Tendon Repair Augmentation
Vergenix
GFD
Growth Factor Delivery
Investor Relations
Financial Reports
Analyst Coverage
Investor FAQs
Investor Tools
Company Presentation
IR Contact
General
Newsroom
Press Releases
Articles
Publications
Peer Reviewed Journals
Oral presentations
Poster Presentations
Prizes
Events
Videos
Contact Us
Open Positions
is a medical device company focused on advancing regenerative medicine by utilizing its proprietary processing technologies for human collagen and other recombinant proteins. The company is developing a substantial range of biomaterials-based products applicable in multiple medical markets, including orthopaedics, wound management, cardiology and general surgery.
Our Mission
seeks to reshape the field of tissue repair through innovative, safe and readily-available products.
Our Products
CollPlant develops advanced wound management products including Vergenix™ Wound Dressing matrix, and an injectable form for deep or irregular wounds.
read more
CollPlant is developing soft and hard tissue repair products, including bone void fillers suturable scaffolds for tendon and ligament repair, and collagen microspheres for growth factor delivery.
read more
News
1/4/2012
CollPlant begins Phase I wound treatment trial
The company recruited the first two patients with diabetic foot ulcers for its recombinant human collagen wound dressing matrix.
12/25/2011
CollPlant to develop orthopedic product with Pfizer
8/28/2011
The company is pleased to announce the appointment of Einat Frydman as Vice-President of Operations of CollPlant Ltd.
8/10/2011
An agreement has been signed between CollPlant Ltd and Gavish - Galilee Bio-Applications Ltd,
regarding Research & Development for the expression of human elastin from transgenic plants .
6/26/2011
CollPlant Ltd. has successfully completed the initial stages of its formulation co-development agreement with Pfizer Inc.
5/23/2011
The research committee of the Industrial R&D administration in the Ministry of Industry, Trade and Labor, approved funding to CollPlant for 2011
12/26/2010
CollPlant Signs Cardiovascular Co-Development Agreement With Edwards Lifesciences
8/29/2010
FDA Rules CollPlant wound dressing a device
6/10/2010
CollPlant’s CSO, Prof. Oded Shoseyov, receives Kaye Award